EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BioNexus Gene Lab's enterprise value is $1.99 Mil.
BioNexus Gene Lab's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $9.78 Mil. Therefore, BioNexus Gene Lab's EV-to-Revenue for today is 0.20.
The historical rank and industry rank for BioNexus Gene Lab's EV-to-Revenue or its related term are showing as below:
BGLC'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.05 Med: 15.88 Max: 38.38
Current: 0.2
During the past 6 years, the highest EV-to-Revenue of BioNexus Gene Lab was 38.38. The lowest was -0.05. And the median was 15.88.
BGLC's EV-to-Revenue is ranked better than 93.81% of 1535
companies
in the Chemicals industry
Industry Median: 1.56
vs BGLC: 0.20
The historical data trend for BioNexus Gene Lab's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's EV-to-Revenue
For the Specialty Chemicals subindustry, BioNexus Gene Lab's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's EV-to-Revenue Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's EV-to-Revenue falls into.
BioNexus Gene Lab's current Enterprise Value is $1.99 Mil.
BioNexus Gene Lab's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab's share price for today is $0.4248.
BioNexus Gene Lab's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 